Yantai Dongcheng Dayang Pharmaceutical Co. Ltd.

Primary Objective: This study used eltogliflozin tablets [5 mg (calculated as C22H25ClO7)] developed by Yantai Dongcheng Dayang Pharmaceutical Co., Ltd. as the test formulation, and eltogliflozin tablets [5 mg (calculated as eltogliflozin), brand name: STEGLATRO®] certified by Merck Sharp & Dohme B.V. as the reference formulation, in accordance with relevant regulations for bioequivalence studies, to evaluate the bioequivalence of the test and reference formulations after administration under fasting conditions. Secondary Objective: To observe the safety of the test and reference formulations, eltogliflozin tablets (STEGLATRO®), in healthy trial participants.

Primary objective: To evaluate the efficacy of dapoxetine (Dapoxetine Alpha) in treating renal anemia (hemodialysis) compared with dapoxetine (Dapoxetine Alpha) injection. Secondary objective: To evaluate the safety of dapoxetine in treating renal anemia (hemodialysis). To evaluate the effect of dapoxetine on iron metabolism.

Primary Objective To compare the extent and rate of absorption of dapoxetine tablets (4 mg) provided by Shandong Bio-Pharmaceutical Co., Ltd. and dapoxetine tablets (4 mg, trade name: Duvroq) licensed by Gracso Smythcraft Co., Ltd. in healthy adults under fasting and fed conditions, and to evaluate their bioequivalence. Secondary Objective To evaluate the safety of dapoxetine tablets (4 mg) provided by Shandong Bio-Pharmaceutical Co., Ltd. and dapoxetine tablets (4 mg, trade name: Duvroq) licensed by Gracso Smythcraft Co., Ltd. in healthy adults under fasting and fed conditions.